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The physiological expression of inducible nitric
oxide synthase (iNOS) in the human colon
P J Roberts, G P Riley, K Morgan, R Miller, J O Hunter, S J Middleton
Abstract
Background—Inducible nitric oxide syn-
thase (iNOS) is expressed in the colonic
epithelium in both inflammatory bowel
disease and colorectal cancer. Nitric oxide
(NO), the product of this enzyme, has
been implicated in the pathogenesis of
both conditions. However, there are con-
flicting data on whether iNOS is expressed
in the normal, uninflamed human colon.
Aims—To evaluate the expression of iNOS
in histologically normal, non-inflamed
human colonic mucosa.
Patients/Methods—Reverse transcription
polymerase chain reaction (RT-PCR), im-
munoblotting, and immunohistochemis-
try were used to investigate the expression
of iNOS in 17 histologically normal speci-
mens obtained at colectomy performed
for colorectal neoplasia. In addition, 16
endoscopic mucosal biopsies, taken from
normal individuals, were also evaluated.
Eleven surgical specimens and 16 endo-
scopic biopsies from patients with refrac-
tory ulcerative colitis were used as
inflammatory controls.
Results—All types of specimens expressed
iNOS mRNA. Immunoblotting revealed a
protein of approximately 130 kDa consist-
ent with iNOS in mucosal extracts of 77%
of normal individuals, and 85% of dis-
eased controls. Immunolabelling localised
this protein to the surface epithelium in
most of the normal specimens and also to
the crypt epithelium and inflammatory
cells in the diseased controls.
Conclusions—These findings provide evi-
dence that iNOS is often expressed in the
surface epithelium of non-inflamed
human colon, suggesting that it is induced
by local luminal factors, such as bacterial
lipopolysaccharide (endotoxin). The re-
sultant NO produced at this site might act
as an oxidative barrier, reducing bacterial
translocation and providing a means of
defence against pathogenic microorgan-
isms.
(J Clin Pathol 2001;54:293–297)
Keywords: inducible nitric oxide synthase; ulcerative
colitis; nitric oxide; colorectal carcinoma
Nitric oxide (NO) is produced by the oxidation
of the guanidino nitrogen atom of L-arginine
by the nitric oxide synthases (NOS).1 These are
broadly categorised into calcium dependent
constitutive isoforms (endothelial NOS
(eNOS) and neuronal NOS (nNOS)) and the
calcium independent inducible isoform
(iNOS), which is produced by a variety of
mammalian cells as a result of cytokine and/or
bacterial endotoxin stimulation.2–4 iNOS ex-
pression in the human colon is believed to be
dependent upon inflammatory conditions such
as those occurring in ulcerative colitis.5–14
However, recent evidence suggests that iNOS
is constitutively expressed in some tissues, such
as the epithelium of human lung,15 and in the
mouse ileal mucosa,16 with the plausible
hypothesis that luminal antigens provide the
stimulus for iNOS expression at these sites.
The colonic epithelium is continuously
exposed to a variety of luminal factors (which
might be modified by diet—for example,
bacterial endotoxin), with the potential for
iNOS induction. Rat colonic epithelial cells in
culture express iNOS in the presence of bacte-
rial endotoxin.17 Whether this isoform is
expressed in a constitutive manner in the
human colon is still a matter of debate, with
conflicting data in the literature. In one study,
iNOS was found in all normal mucosal
specimens evaluated, whereas it was absent
from cancer specimens.18 Another study, com-
paring the expression of this isoform in normal
colon, adenomas, and carcinomas, gave con-
trasting results in that little or no expression
was found in normal tissue.19 Therefore, we
evaluated iNOS expression in the normal
human colon as detailed below.
Patients and specimens
SURGICAL SPECIMENS
Histologically normal tissue was obtained dur-
ing colectomy from patients with colorectal
neoplasia from a site distant from the lesion.
Full thickness biopsies were taken in four of
these patients before colectomy, to control for
any possible eVect of surgical manipulation on
iNOS expression. Surgical specimens from
patients with refractory ulcerative colitis were
used as inflammatory controls, with all patients
receiving the same bowel preparation before
surgery (table 1). Tissues were frozen immedi-
ately and stored at −70°C until analysis.
ENDOSCOPIC BIOPSIES
Histologically normal mucosal biopsies ob-
tained at rigid sigmoidoscopy (n = 8) and
colonoscopy (n = 8) were obtained from pa-
tients attending the outpatient department
who were later shown to have normal colons on
either barium enema or full colonoscopy. It was
felt necessary to analyse endoscopic biopsies
from these normal colons because they were
not influenced by any local carcinogenic
factors or surgical stress and manipulation, two
possible stimulants that might have influenced
iNOS expression in the surgical specimens.
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Inflamed mucosal biopsies from patients with
active ulcerative colitis (n = 11) served as
disease controls. All endoscopic biopsies were
snap frozen in liquid nitrogen and postfixed in
fresh 1% paraformaldehyde pending immuno-
histochemical evaluation.
Materials and methods
REVERSE TRANSCRIPTION POLYMERASE CHAIN
REACTION (RT-PCR)
Total RNA was purified from 200 mg of frozen
tissue according to the method of Chomczyn-
ski and Sacchi.20 Extracted RNA pellets were
washed in 70% ethanol, dissolved in sterile
water, and stored at −70°C until evaluated.
Aliquots of each RNA sample (5 µg) were
reverse transcribed to produce single stranded
cDNA using random primers and AMV
reverse transcriptase (Invitrogen, Leek, the
Netherlands). Samples of cDNA (50 ng) were
then analysed by PCR amplification using
iNOS specific nucleotide primers and BioTaq
DNA polymerase (Bioline, London, UK).
Primer sequences were as follows: iNOS sense,
5'-GAG AAA GCC CCC TGT GCC-3' and
iNOS antisense, 5'-TAC CGC TTC CAC
CCT GGC-3', which amplify a 424 bp cDNA
fragment. PCR amplification was carried out
for up to 45 cycles as follows: after five minutes
denaturation at 93°C, hot start reactions were
initiated (annealing 60°C for 30 seconds,
extension 72°C for 30 seconds, and denatura-
tion 93°C for 30 seconds). Semiquantitative
PCR data were generated by kinetic analysis
and compared with glyceraldehyde-3-
phosphate dehydrogenase (G3PDH) mRNA
values. Products were analysed by 6% poly-
acrylamide gel electrophoresis and film autora-
diography using radiolabelled DNA size mark-
ers (100 bp ladder from Gibco-BRL, Paisley,
UK). Products separated in this way were
excised, eluted from the gel into 0.5 M ammo-
nium acetate, and ethanol precipitated. The
identity of the product was confirmed by direct
cycle sequencing using a kit (Circumvent; New
England Biolabs, Hitchin, UK).
IMMUNOHISTOCHEMISTRY
iNOS expression and cellular localisation were
examined in tissue by immunoperoxidase
labelling. Frozen surgical specimens were
sectioned and then postfixed in 1% parafor-
maldehyde. Non-surgical biopsy specimens
were frozen and postfixed in 1% paraformalde-
hyde. Endogenous peroxidase activity was
blocked in the tissue sections, (10 µm section
on APES coated slides), using the endogenous
peroxidase suppressor “Immunopure” (Pierce
Laboratories, Chester, UK) for 22 minutes,
followed by the application of a 1/20 dilution of
normal goat serum to block non-specific stain-
ing. The primary antibody, a rabbit polyclonal
raised against a peptide corresponding to
amino acids 3–22 mapping to the N-terminus
of human iNOS, was obtained from Santa
Cruz, Santa Cruz, California, USA (N-20).
This was applied to sections at a concentration
of 0.5–1 µg/ml and incubated for one hour.
Subsequently, the second antibody was ap-
plied, a goat antirabbit biotinylated antibody
(applied at 5 µg/ml; Vecta Laboratories, Cali-
fornia, USA). This was probed further with AB
vectastain and developed with diaminobenza-
dene (DAB) for three to five minutes, giving a
brown stain at sites of immunolabelling.
Normal rabbit serum (concentration up to
2 µg/ml) was applied on serial sections as a
negative control. As an additional control of
specificity of labelling, it was ensured that any
positive labelling was neutralised by preabsorp-
tion of the primary antibody with iNOS
peptide. Sections were counterstained with
haematoxylin (1/20 dilution).
EXTRACTION AND IMMUNOBLOTTING OF iNOS
The monospecificity of the primary iNOS
antibody (Santa Cruz N-20) used was initially
assessed by immunoblots. Purified human
recombinant iNOS, eNOS, and nNOS ob-
tained from transfected insect cells were used
as standards (donated by R Knowles, Glaxo-
Wellcome, Stevenage, UK). No cross reactivity
was seen with the eNOS and nNOS standards,
but strong labelling was seen with the purified
iNOS (data not shown). This protein was used
as a positive standard for tissue blots.
TISSUE EXTRACTION
Colonic mucosa was homogenised in ice cold
RIPA buVer containing 25 mM Tris, pH 6.8,
1 mM EDTA, 0.1% sodium dodecyl sulphate
(SDS), 1% NP40, 1% sodium deoxycholate,
and 0.9% NaCl. Protease inhibitors were
added as follows: 100 µg/ml phenylmethyl-
sulphonylflouride (PMSF), aprotinin contain-
ing 5–10 trypsin inhibitor units (TIU)/ml
diluted to 30 µl/ml, 1 µg/ml pepstatin, 0.5 µg/
ml leupeptin, and 625 µg/ml n-ethylmaleimide.
Samples for SDS polyacrylamide gel electro-
phoresis (SDS-PAGE) were solubilised in
sample buVer containing 62.5 mM Tris/HCl,
10% glycerol, 2% SDS, 0.1% bromophenol
blue, and 100 mM dithiotreitol (DTT),
pH 6.8. Equal amounts of protein (20 µg) for
each homogenate were loaded on to 7.5%
Table 1 Surgical specimens
Histologically normal specimens Specimens from patients with UC
Mean age (years) 55 (range, 40–78) 40 (range, 33–60)
Sex 9 men, 8 women 6 men, 5 women
Medication Nil Azathioprine (dose, 2.5 mg/kg; n = 6)
5-ASA (dose, 2.4 g/day; n = 11)
Methylpredisolone (mean dose, 500 mg/day; n = 11)
Site of disease Left sided neoplasm (n = 9) Pancolitis (n = 11)
Right sided neoplasm (n = 8)
Histological diagnosis Tubulovillous adenoma (n = 3) Active ulcerative colitis (n = 11)
Adenocarcinoma (n = 14)
5-ASA, 5 aminosalicylic acid; UC, ulcerative colitis.
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SDS-PAGE gels and electrophoresed. Sepa-
rated proteins were transferred to nitrocellu-
lose membrane (Amersham, UK). The mem-
brane was incubated with iNOS primary
antibody (as described above) at a similar con-
centration (1 µg/ml) to that used for immuno-
staining, followed by probing with a goat anti-
rabbit antibody (diluted 1/5000) linked to
horseradish peroxidase (Vecta Laboratories).
Blots were developed by enhanced chemilu-
minescence (ECL; Amersham, Amersham,
UK).
Results
iNOS mRNA expression was detected in all
specimens, both normal and inflamed, using
RT-PCR (fig 1). Kinetic PCR analysis revealed
increased iNOS production in the inflamed tis-
sues compared with normal tissue when stand-
ardised to G3PDH, consistent with previous
data7 (fig 2). Immunoblotting revealed the
presence of a protein of approximately
130 kDa in 77% of normal and 85% of
diseased specimens, which was shown to comi-
grate with the iNOS standard. The presence of
this band was inhibited by the addition of a 2×
concentration of the immunising N-20 peptide
(Santa Cruz) (fig 3). Immunostaining localised
iNOS protein to the surface epithelium in 80%
of the histologically normal surgical specimens
and in 90% of the normal endoscopic biopsies.
Additional labelling was seen in the crypt
epithelium and inflammatory cells of the
lamina propria in inflamed mucosa in 85% of
the surgical and in 93% of the endoscopic
biopsy specimens (fig 4), irrespective of any
treatment the patients with ulcerative colitis
received before surgery. For all specimens
staining positive, the immunolabelling was
neutralised when antibody was preabsorbed
with the N-20 iNOS peptide.
Discussion
Our data demonstrate that iNOS is expressed
not only in inflamed mucosa in ulcerative coli-
tis, but also in the epithelium of the non-
inflamed human colon, as suggested by one
previous study, although that report was
limited by using immunohistochemistry alone
and small numbers of patients.18 A further
report suggested that iNOS enzyme activity
was present in the mucosa of a few normal
specimens, although they were unable to dem-
onstrate iNOS protein expression itself in these
specimens.19 This study also suggested that
colonic iNOS expression was related to the
stage of cancer development, with the highest
degree of expression seen in adenomas; that is,
precancerous lesions. Our surgical specimens
were taken from patients with colorectal cancer
or adenomas, although tissue was obtained
from a site distant from the lesion. Because
local carcinogenic factors might play a role in
iNOS induction, we also examined colonic tis-
sue taken endoscopically from patients shown
to have completely normal colons, thereby
eliminating such eVects. All other studies have
failed to demonstrate iNOS expression in the
normal colon,5–14 and have therefore not
confirmed the initial report.18
Figure 1 Qualitative RT-PCR analysis of inducible nitric oxide synthase (iNOS)
expression in surgical specimens showing the ubiquitous presence of a 424 bp DNA product
indicating iNOS expression.MW,molecular weight markers (indicating 400 bp left lane).
Lanes 1–6, normal tissue; lanes 7, 9, and 10, diseased specimens; lane 8, negative control.
400 bp
MW 1 2 3 4 5 6 7 8 9 10
Figure 2 Example of kinetic PCR analysis of inducible nitric oxide synthase (iNOS) expression in a diseased (left hand
set) and a normal specimen (right hand set). Densitometrical analysis revealed the expected increase of iNOS product in
diseased tissue compared with normal tissue. PCR cycle lengths: G3PDH, 30–34; iNOS, 41–45.G3PDH,
glyceraldehyde-3-phosphate dehydrogenase.
400 bp
30 34 41 45 30 34 41 45
G3PDH iNOS G3PDH iNOS
Figure 3 Immunoblotting of surgical mucosal specimens
with primary anti-inducible nitric oxide synthase (iNOS)
antibody showing band of approximately 130 kDa
expressed in normal mucosa, consistent with full length
iNOS protein expression. Lanes 1 and 2, normal mucosa;
lane S, iNOS recombinant protein standard (smaller sized
bands indicating iNOS degradation on storage). Lane P
shows immunoreactivity of iNOS inhibited by coincubation
with the immunising peptide.
200 bp
iNOS
1 2 S P
131 bp
80 bp
40 bp
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The expression of iNOS in the normal
colonic epithelium is likely to occur in response
to luminal factors, such as bacterial lipopoly-
saccharide (LPS), which are the only locally
occurring substances known to induce iNOS.
In some ways, this is similar to the expression of
iNOS in the epithelium of normal lung, which
also occurs in close proximity to such stimu-
lants. All normal specimens expressed iNOS
mRNA, with iNOS protein expression in most
of these specimens being evaluated. Interest-
ingly, the localisation of iNOS was found to be
patchy along the surface epithelium, a feature
that we as yet cannot explain. Therefore, it
would seem necessary to evaluate large num-
bers of specimens and to use multiple tech-
niques to obtain representative data in the nor-
mal human colon, as illustrated by our study.
Epithelial cell derived NO could provide an
oxidative barrier, thereby reducing bacterial
translocation through the colonic mucosa and
might, therefore, be viewed as part of the local
colonic barrier system. However, high concen-
trations of NO might be cytopathic to epithe-
lial cells at this site, either directly, or as a
result of its reaction with superoxide radicals
to form peroxynitrite, as occurs in inflamma-
tory conditions of the colon.2 7 21 In high con-
centrations, NO will also induce apoptosis in
some mammalian cells,22 whereas evidence is
accumulating to suggest that inhibition of
apoptosis occurs at lower concentrations of
NO.23–26 At the cellular level, the chemistry of
NO is ill defined and complex,26 27 with the
potential of NO either to induce or inhibit
apoptosis in the normal colonic epithelium,
depending upon the luminal and cellular
microenvironment.
Other pathophysiological eVects of NO and
its oxides include nitrosation of amines,21 28–30
which in the colonic epithelium would lead to
increased concentrations of luminal nitro-
samines with their carcinogenic potential. In
addition, NO has been shown to deaminate
DNA bases, thereby having the potential to
alter the genome directly.31 32
Dietary factors are implicated in colorectal
carcinoma,33 34 including red meat, which
increases faecal concentrations of N-nitroso
compounds.35 The mechanism by which this
increase in nitrosamine concentration occurs is
uncertain, but may be via epithelial iNOS
expression, with resultant nitrosation of lumi-
nal amines by NO, thus creating a luminal
microenvironment that is more likely to lead to
carcinogenesis.35
In summary, using multiple techniques we
have shown the expression of iNOS in the
mucosa of normal human colon in a large
number of specimens. The resultant NO
produced by this enzyme might have beneficial
eVects by both maintaining epithelial barrier
function, with prevention of bacterial translo-
cation, and by stimulating apoptosis. Con-
versely, in certain luminal environments, epi-
thelial NO might be carcinogenic to colonic
epithelial cells. Therefore, mucosal iNOS
expression might be a link between diet or
some other luminal component and colorectal
carcinogenesis. Further studies are required to
identify possible stimulants of iNOS induction
in the normal colon, whether dietary or another
luminal factor, and to evaluate the eVects of
this iNOS expression in the normal colonic
epithelium with regard to apoptosis and
carcinogenesis.
Figure 4 Immunolocalisation of inducible nitric oxide synthase (iNOS) in surgical specimens showing surface epithelial
staining in the normal tissue, and more extensive labelling in the diseased tissue. (A) Non-immune serum, normal mucosa;
(B) iNOS expression, normal mucosa; (C) control (primary antibody quenched with 2× concentration of immunising
peptide), normal mucosa; (D) iNOS expression, diseased mucosa. Original magnification ×120 (A, C, and D,); original
magnification ×240 (B).
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